Loading clinical trials...
Loading clinical trials...
A Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Ascending Doses of GSK2018682 (S1P1 Agonist) in Healthy Volunteers
Conditions
Interventions
GSK2018682
Placebo
Locations
3
Australia
GSK Investigational Site
Randwick, New South Wales, Australia
GSK Investigational Site
Adelaide, South Australia, Australia
GSK Investigational Site
Nedlands, Western Australia, Australia
Start Date
October 10, 2010
Primary Completion Date
March 29, 2011
Completion Date
March 29, 2011
Last Updated
July 7, 2017
NCT05359653
NCT06390930
NCT03401879
NCT06389968
NCT05834855
NCT06413602
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions